Selena Simmons-Duffin

Yeah, exactly. They took that position in a filing on Monday. And this was a bit surprising because that's the same position the Biden administration's Justice Department had made. And you might not expect a lot of continuity when it comes to abortion between these two administrations.

Yeah, exactly. They took that position in a filing on Monday. And this was a bit surprising because that's the same position the Biden administration's Justice Department had made. And you might not expect a lot of continuity when it comes to abortion between these two administrations.

Yeah, I don't think that's necessarily what it means. That's in part because the federal judge in Texas who's presiding, Judge Matthew Kesmarek, is known to be very receptive to anti-abortion arguments. So this case might continue regardless of what the Trump administration wants to do.

Yeah, I don't think that's necessarily what it means. That's in part because the federal judge in Texas who's presiding, Judge Matthew Kesmarek, is known to be very receptive to anti-abortion arguments. So this case might continue regardless of what the Trump administration wants to do.

Yeah, I don't think that's necessarily what it means. That's in part because the federal judge in Texas who's presiding, Judge Matthew Kesmarek, is known to be very receptive to anti-abortion arguments. So this case might continue regardless of what the Trump administration wants to do.

Also, this is not the only tool in the Trump administration's toolbox when it comes to restricting abortion cases. Katie Keith is the director of the Georgetown Center for Health Policy and the Law and formerly served on Biden's Gender Policy Council. I would say the jury is still out, essentially, of how aggressive the Trump administration is going to be on medication abortion.

Also, this is not the only tool in the Trump administration's toolbox when it comes to restricting abortion cases. Katie Keith is the director of the Georgetown Center for Health Policy and the Law and formerly served on Biden's Gender Policy Council. I would say the jury is still out, essentially, of how aggressive the Trump administration is going to be on medication abortion.

Also, this is not the only tool in the Trump administration's toolbox when it comes to restricting abortion cases. Katie Keith is the director of the Georgetown Center for Health Policy and the Law and formerly served on Biden's Gender Policy Council. I would say the jury is still out, essentially, of how aggressive the Trump administration is going to be on medication abortion.

She says if they want to restrict access, they could. For example, the Trump administration's FDA could just go ahead and add restrictions on who can get this medication and how without being required to by the court.

She says if they want to restrict access, they could. For example, the Trump administration's FDA could just go ahead and add restrictions on who can get this medication and how without being required to by the court.

She says if they want to restrict access, they could. For example, the Trump administration's FDA could just go ahead and add restrictions on who can get this medication and how without being required to by the court.

You know, it's hard to predict. The new FDA commissioner, Marty McCary, said publicly in April there were, quote, no plans for FDA to restrict mifeprostone, but plans can change. This is a medication that's been approved for almost 25 years. It's been found to be safe and effective in ending a pregnancy, along with another medication called misoprostol. And it's a medication that's used globally.

You know, it's hard to predict. The new FDA commissioner, Marty McCary, said publicly in April there were, quote, no plans for FDA to restrict mifeprostone, but plans can change. This is a medication that's been approved for almost 25 years. It's been found to be safe and effective in ending a pregnancy, along with another medication called misoprostol. And it's a medication that's used globally.

You know, it's hard to predict. The new FDA commissioner, Marty McCary, said publicly in April there were, quote, no plans for FDA to restrict mifeprostone, but plans can change. This is a medication that's been approved for almost 25 years. It's been found to be safe and effective in ending a pregnancy, along with another medication called misoprostol. And it's a medication that's used globally.

The World Health Organization says it can be used safely in the first trimester of pregnancy without the direct supervision of a healthcare provider. The FDA here in this country made the same determination. And what's happened since Roe v. Wade was overturned nearly three years ago

The World Health Organization says it can be used safely in the first trimester of pregnancy without the direct supervision of a healthcare provider. The FDA here in this country made the same determination. And what's happened since Roe v. Wade was overturned nearly three years ago

The World Health Organization says it can be used safely in the first trimester of pregnancy without the direct supervision of a healthcare provider. The FDA here in this country made the same determination. And what's happened since Roe v. Wade was overturned nearly three years ago

is that half of states have banned abortion, but the total number of abortions nationally has gone up, in part because people have been able to get this medication through the mail. There are a lot of ways that the Trump administration could try to tamp down on that outside of this court case if it wants to, and that's what remains to be seen.

is that half of states have banned abortion, but the total number of abortions nationally has gone up, in part because people have been able to get this medication through the mail. There are a lot of ways that the Trump administration could try to tamp down on that outside of this court case if it wants to, and that's what remains to be seen.

is that half of states have banned abortion, but the total number of abortions nationally has gone up, in part because people have been able to get this medication through the mail. There are a lot of ways that the Trump administration could try to tamp down on that outside of this court case if it wants to, and that's what remains to be seen.